A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase ??? Study to Evaluate the Efficacy and Safety of JW0201 Added on in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with C2202 and C2203
Latest Information Update: 11 Nov 2024
At a glance
- Drugs JW 0201 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors JW Pharmaceutical
Most Recent Events
- 07 Nov 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Nov 2024.
- 07 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2023 New trial record